| Visual acuity, ECD, ECL and complications | |
|---|---|
| Postoperative UCVA (n=99) | – |
| ▪ 20/25 or better | 27 (27.3% |
| ▪ 20/30 to 20/60 | 55 (55.6%) |
| ▪ <20/60 to 20/200 | 18 (18.2%) |
| ▪ <20/200 | 09 (9.1%) |
| Postoperative BSCVA (n=99) | – |
| ▪ 20/25 or better | 57 (57.6%) |
| ▪ 20/30 to 20/60 | 27 (31.4%) |
| ▪ <20/60 to 20/200 | 10 (10.2%) |
| ▪ <20/200 | 05 (5.1%) |
| Endothelial cell density – Donor | – |
| [Cells/sq mm; Mean ± SD (range)] | 2891 ± 227 (2500 – 3717) |
| Endothelial cell density – after 3 months | – |
| [Cells/mm2; Mean ± SD (range)] | 2123 ± 438 (976 – 3208) |
| Endothelial cell loss (ECL) | – |
| Percentage; Mean ± SD (range) | 26.92 ± 13.40 (4.90% – 66.6%) |
| Complications - n; (%) | – |
| ▪ Graft damaged during preparation | 3 (3%) |
| ▪ Graft damaged during unscrolling | 2 (2%) |
| ▪ Pupillary block | 2 (2%) |
| ▪ Detachment of DM graft | – |
| Total | 1 (1%) |
| Partial central | 2 (2%) |
| Partial peripheral | 6 (6%) |
| ▪ Iatrogenic primary donor failure | 1 (1%) |
| ▪ Secondary glaucoma | 7 (7%) |
| ▪ HSV recurrence | 1 (1%) |
| ▪ Infection/rejection | Nil 19 |
| ▪ Comorbid other ocular conditions | (19%) |
| Reoperations required: | – |
| ▪ Rebubbling | 4 (4%) |
| ▪ Re DMEK | 1 (1%) |
| UCVA: Uncorrected Visual Acuity; BSCVA: Best Spectacle Corrected Visual Acuity; DM: Descemet Membrane; HSV: Herpes Simplex Virus | |